These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16920253)

  • 41. Endoscopic management of upper tract urothelial carcinoma in patients with a history of bladder urothelial carcinoma.
    Krambeck AE; Thompson RH; Lohse CM; Patterson DE; Segura JW; Zincke H; Elliott DS; Blute ML
    J Urol; 2007 May; 177(5):1721-6. PubMed ID: 17437796
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes.
    Boudreaux KJ; Chang SS; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Clark PE
    Cancer; 2009 Feb; 115(4):770-5. PubMed ID: 19152431
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
    Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J
    Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
    Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
    J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder.
    Cho KS; Seo JW; Park SJ; Lee YH; Choi YD; Cho NH; Yang SC; Hong SJ
    Urol Int; 2009; 82(3):306-11. PubMed ID: 19440019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
    Sabichi AL; Lerner SP; Atkinson EN; Grossman HB; Caraway NP; Dinney CP; Penson DF; Matin S; Kamat A; Pisters LL; Lin DW; Katz RL; Brenner DE; Hemstreet GP; Wargo M; Bleyer A; Sanders WH; Clifford JL; Parnes HL; Lippman SM
    Clin Cancer Res; 2008 Jan; 14(1):224-9. PubMed ID: 18172274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population-based molecular prognosis of breast cancer by transcriptional profiling.
    Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
    Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
    Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
    Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recurrence-free survival after radical cystectomy of patients downstaged by transurethral resection.
    Nielsen ME; Bastian PJ; Palapattu GS; Trock BJ; Schoenberg MP; Chan T; Rogers CG
    Urology; 2007 Dec; 70(6):1091-5. PubMed ID: 18158024
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.
    Weiss C; von Römer F; Capalbo G; Ott OJ; Wittlinger M; Krause SF; Sauer R; Rödel C; Rödel F
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1455-60. PubMed ID: 19231102
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
    Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
    J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activation of RAS family genes in urothelial carcinoma.
    Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
    J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?
    Denzinger S; Fritsche HM; Otto W; Blana A; Wieland WF; Burger M
    Eur Urol; 2008 Jan; 53(1):146-52. PubMed ID: 17624657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. E-cadherin mRNA expression analysis in evaluating the natural history of urothelial bladder cell carcinoma: results from a long-term follow-up study.
    Cai T; Piazzini M; Nesi G; Taddei I; Sardi I; Detti B; Mondaini N; Dal Canto M; Bartoletti R
    Oncol Rep; 2007 Apr; 17(4):925-30. PubMed ID: 17342338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?
    Brown GA; Busby JE; Wood CG; Pisters LL; Dinney CP; Swanson DA; Grossman HB; Pettaway CA; Munsell MF; Kamat AM; Matin SF
    BJU Int; 2006 Dec; 98(6):1176-80. PubMed ID: 17125474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
    Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance.
    Tran W; Serio AM; Raj GV; Dalbagni G; Vickers AJ; Bochner BH; Herr H; Donat SM
    J Urol; 2008 Jan; 179(1):96-100. PubMed ID: 17997449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy.
    Li WM; Li CC; Ke HL; Wu WJ; Huang CN; Huang CH
    J Urol; 2009 Aug; 182(2):451-8; discussion 458. PubMed ID: 19524962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.